After 15 Years at Exelon's Helm, CIO Doug Brown Retires
Legendary Exelon chief investment officer Doug Brown has announced his plans to retire after 15 years at the helm. Brown will hand over the reins to Exelon’s vice president of investment strategy and public markets, Jessica Hart, on July 1. Hart joined the pension, which manages more than $20…#legendaryexelon #dougbrown #jessicahart #hart #northerntrusts #cio #francisidehen #dougs #constellation #constellationscio (Source: Reuters: Health)
Source: Reuters: Health - February 29, 2024 Category: Consumer Health News Source Type: news
SEC charges ComEd, former CEO in Madigan scandal
The Commonwealth Edison scandal engulfing indicted former Illinois House Speaker Michael Madigan is now costing its parent company, Exelon Corp., $46.2 million in penalties under a new settlement with the federal Securities and Exchange Commission. The SEC charged Exelon and ComEd with fraud in…#commonwealthedison #illinoishouse #michaelmadigan #exeloncorp #madigan #generalassembly #annepramaggiore #exhouse #comed #pramaggiore (Source: Reuters: Health)
Source: Reuters: Health - September 30, 2023 Category: Consumer Health News Source Type: news
Exelon to pay $46.2M penalty to settle SEC fraud charges
(Source: Reuters: Health)
Source: Reuters: Health - September 28, 2023 Category: Consumer Health News Source Type: news
Exelon CEO on the Inflation Reduction Act and the Infrastructure Investment and Jobs Act
Cramer spoke with Exelon CEO Calvin Butler Jr. on Monday.#exelon #calvinbutlerjr (Source: Reuters: Health)
Source: Reuters: Health - January 10, 2023 Category: Consumer Health News Source Type: news
A New Generation of Nuclear Reactors Could Hold the Key to a Green Future
On a conference-room whiteboard in the heart of Silicon Valley, Jacob DeWitte sketches his startup’s first product. In red marker, it looks like a beer can in a Koozie, stuck with a crazy straw. In real life, it will be about the size of a hot tub, and made from an array of exotic materials, like zirconium and uranium. Under carefully controlled conditions, they will interact to produce heat, which in turn will make electricity—1.5 megawatts’ worth, enough to power a neighborhood or a factory. DeWitte’s little power plant will run for a decade without refueling and, amazingly, will emit no carbon. &...
Source: TIME: Science - November 16, 2021 Category: Science Authors: Andrew Blum Tags: Uncategorized biztech2030 climate change Source Type: news
Guest Notebook: Exelon Utilities CEO Calvin Butler shares his thoughts on getting the Covid-19 vaccine
I recently got my second Pfizer vaccination shot at M&T Bank Stadium in Baltimore. If anyone is hesitant about receiving the Covid-19 vaccine, I ’m glad to share the steps I took to protect my family, our team at Exelon Uilities and the communities we serve.
I had a few reasons for getting vaccinated as soon as I was eligible. I’m a social person and I miss the interaction with our teams and our communities. I want to be able to be pr esent — in person — as soon as possible. To do that,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 10, 2021 Category: American Health Authors: Calvin Butler Source Type: news
Amneal wins FDA nod for generic rivastigmine transdermal patch
Amneal Pharmaceuticals (NYSE:AMRX) said today that it won FDA approval for a generic rivastigmine transdermal patch.
The drug, which is sold under the brand name Exelon, is an acetylcholinesterase inhibitor that is commonly used to treat mild to moderate Alzheimer’s disease and Parkinson’s disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Amneal wins FDA nod for generic rivastigmine transdermal patch appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 14, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat amnealpharmaceuticals Source Type: news
Amneal Announces Approval of Rivastigmine Transdermal System
BRIDGEWATER, N.J., Jan. 14, 2019 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 m... Biopharmaceuticals, Drug Delivery, Generics, FDA Amneal Pharmaceuticals, Rivastigmine, Transdermal (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 14, 2019 Category: Pharmaceuticals Source Type: news
Mylan launches generic drug-delivery patch for dementia patients
Mylan (NSDQ:MYL) announced today the U.S. launch of its rivastigmine transdermal drug-delivery patch, a generic version of Novartis‘ (NYSE:NVS) Exelon therapy.
The company’s rivastigmine therapy is indicated for the treatment of dementia associated with Alzheimer’s disease and Parkinson’s disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan launches generic drug-delivery patch for dementia patients appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 9, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat Mylan Novartis Source Type: news
Exelon (Rivastigmine Tartrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 7, 2017 Category: Drugs & Pharmacology Source Type: news
Novartis slapped with $49m fine over kickbacks
South Korea regulators said today that it fined Swiss drugmaker Novartis (NYSE:NVS)$48.8 million for offering doctors kickbacks in exchange for recommending the company’s drugs to patients.
The Ministry of Health and Welfare also decided to suspend insurance coverage of 9 variations of 2 drugs, including the Alzheimer’s drug Exelon, for 6 months, according to Reuters.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartis slapped with $49m fine over kickbacks appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 27, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Pharmaceuticals Regulatory/Compliance Wall Street Beat Novartis Source Type: news
Exelon (rivastigmine, Exelon Patch)
Title: Exelon (rivastigmine, Exelon Patch)Category: MedicationsCreated: 10/19/2003 12:00:00 AMLast Editorial Review: 9/22/2016 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - September 22, 2016 Category: Geriatrics Source Type: news
Treatment of Alzheimer ’ s Disease
There is no cure for Alzheimer’s disease and no way to slow the progression of the disease. For some people in the early or middle stages of Alzheimer’s disease, medication such as tacrine (Cognex) may alleviate some cognitive symptoms. Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) may keep some symptoms from becoming worse for a limited time. A fifth drug, memantine (Namenda), has also been approved for use in the United States.
Combining memantine with other Alzheimer’s disease drugs may be more effective than any single therapy. One controlled clinical trial found that patients...
Source: Psych Central - August 17, 2016 Category: Psychiatry Authors: Jane Framingham, Ph.D. Tags: Alzheimer's Medications Memory and Perception Alzheimer's treatment Cognex donepezil Drug Exelon galanta Namenda Reminyl rivastigmine tacrine treatment of alzheimers Source Type: news
ExxonMobil Is Still Funding Climate Science Denier Groups
ExxonMobil officials may hem and haw when reporters ask them if the company still funds climate science denier organizations, but the numbers don't lie.
The company says it acknowledges the reality of global warming and claims it supports a carbon tax, but its recently disclosed list of 2015 "public information and policy research" grantees shows it spent nearly $2 million last year on more than a dozen think tanks, advocacy groups and associations that dispute climate science and disparage renewable energy.
That's significant from both a legal and political perspective.
There are legal implications because ExxonMobil ...
Source: Science - The Huffington Post - July 13, 2016 Category: Science Source Type: news
Intrigued by the Marriott deal? Here are 5 other M&A deals that captivated Greater Washington
If there's one thing we've learned this month it's that the M&A world isn't for the faint-hearted.
The D.C. Public Service Commission finally ended its will-it-or-won't-it game, giving approval for Pepco Holdings Inc. and Exelon Corp. to close their $6.8 billion merger. Which they did. Within hours.
And Marriott International Inc. was engaged in a high-stakes game of financial chicken with the Chinese insurer Anbang over the potential acquisition of Starwood Hotels & Resorts Worldwide Inc. In the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 1, 2016 Category: Pharmaceuticals Authors: Andy Medici Source Type: news
